Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards
Vaccinex announces Nasdaq delisting due to non-compliance with equity standards; trading shifts to OTC Markets.Quiver AI SummaryVaccinex, Inc., a clinical-stage biotechnology company focused on treating...
Vaccinex, Inc. Reports Q3 Financial Results and Advances Alzheimer’s Development While Exploring Partnership Opportunities
Vaccinex reports promising Alzheimer’s treatment results, financial updates, and plans for partnerships to enhance development.Quiver AI SummaryVaccinex, Inc. has reported its financial results for the...
MarketBeat Week in Review – 2/6 - 2/10
Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely
Should Investors Buy or Sell the Vaccinex Patent News?
Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?